-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DxHBRPBJlm6MMQFZGV9HrUwvLJ53eJpqi3hKFvyurEMLtGcQilHRXLRuTGfqMFx0 RPA6or4AVxQXnej8b2tgNA== 0001299933-06-007077.txt : 20061102 0001299933-06-007077.hdr.sgml : 20061102 20061102160208 ACCESSION NUMBER: 0001299933-06-007077 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20061031 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20061102 DATE AS OF CHANGE: 20061102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOSE TECHNOLOGIES INC CENTRAL INDEX KEY: 0000877902 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133549286 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27718 FILM NUMBER: 061182764 BUSINESS ADDRESS: STREET 1: 102 WITMER RD CITY: HORSHAM STATE: PA ZIP: 19044 BUSINESS PHONE: 2154415890 MAIL ADDRESS: STREET 1: 102 WITMER ROAD CITY: HORSHAM STATE: PA ZIP: 19044 FORMER COMPANY: FORMER CONFORMED NAME: NEOSE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950817 8-K 1 htm_16006.htm LIVE FILING Neose Technologies, Inc. (Form: 8-K)  

 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   October 31, 2006

Neose Technologies, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 000-27718 13-3549286
_____________________
(State or other jurisdiction
_____________
(Commission
______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
102 Witmer Road, Horsham, Pennsylvania   19044
_________________________________
(Address of principal executive offices)
  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   215-315-9000

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 1.01 Entry into a Material Definitive Agreement.

On October 31, 2006, Neose Technologies, Inc. (the "Company") entered into an Amended and Restated Research, Development and License Agreement (the "Amended and Restated Agreement") with Novo Nordisk A/S and Novo Nordisk Health Care AG (collectively Novo Nordisk A/S and Novo Nordisk Health Care AG shall be referred to as "Novo"). The Amended and Restated Agreement supersedes the Research, Development and License Agreement by and between the Company and Novo dated November 17, 2003 (the "Original Agreement"). The Amended and Restated Agreement will be filed as an exhibit to the Company’s annual report on Form 10-K for the year ended December 31, 2006, with portions omitted and filed separately with the Secretary of the Securities and Exchange Commission pursuant to a request for confidential treatment.

The Amended and Restated Agreement incorporates the three prior amendments to the Original Agreement entered into by the Company and Novo on December 18, 2003, October 12, 2004 and December 15, 2005, respectively, and further amends the Original Agreement to clarify certain complex issues surrounding intellectual property. Under the Amended and Restated Agreement, the Company and Novo will continue to conduct work on a next-generation version of coagulation Factor VIIa (the "Product") for which Novo will fund the Company’s research and development activities and potentially pay the Company development milestones. In addition, under the Amended and Restated Agreement, the Company has granted to Novo a license to use the Company’s technology in the Product (the "License") and the Company may receive significant royalties on sales of the Product. The License continues until the expiration of the last Company patent covering a Product, or until the earlier termination of the Amended and Restated Agreement. Novo has the right to terminate the Amended and Restated Agreement without cause.

The Company does not have any material relationship with Novo or its affiliates other than i n respect of the Amended and Restated Agreement and a separate Research, Development and License Agreement by and between the Company and Novo Nordisk A/S dated November 17, 2003 under which the Company is conducting work on next-generation versions of coagulation Factors VIII and IX.

Separately, on October 31, 2006, the Company entered into a Modification Agreement (the "Modification Agreement") with General Electric Capital Corporation ("GE Capital"). GE Capital provided equipment financing to the Company pursuant to a Master Security Agreement dated December 19, 2002 (the "Master Security Agreement") and six promissory notes dated September 17, 2003, December 18, 2003, March 30, 2004, August 20, 2004, December 16, 2004 and July 5, 2005 (collectively, the "Notes"). The Modification Agreement reduced the amount and number of monthly installment payments of principal and interest to be paid by the Company to GE Capital pursuant to each respective Note in connection with the Company’s prepa yment of certain amounts.

The Company does not have any material relationship with GE Capital or its affiliates other than in respect of the Modification Agreement, the Master Lease Agreement, the Notes and related documents.





Item 1.02 Termination of a Material Definitive Agreement.

The information set forth under Item 1.01 of this report is incorporated herein by reference.





Item 9.01 Financial Statements and Exhibits.

The attached Exhibit Index is incorporated herein by reference.





“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Statements in this Current Report on Form 8-K regarding the Company’s business that are not historical facts are “forward-looking statements” that involve risks and uncertainties, including the risk that the collaboration between Novo and the Company will not be successful, the risk that the Company will not successfully develop a next-generation coagulation Factor VIIa and the risk that the Company will not receive any milestones or royalties under the Amended and Restated Agreement . For a discussion of these risks and uncertainties, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statement, see the section entitled “Factors Affecting the Company’s Prospects” in the Company’s Annual Report on Form 10-K for the year ended December 31, 200 5 and discussions of potential risks and uncertainties in the Company’s subsequent filings with the SEC.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Neose Technologies, Inc.
          
November 2, 2006   By:   A. Brian Davis
       
        Name: A. Brian Davis
        Title: Senior Vice President and Chief Financial Officer


Exhibit Index


     
Exhibit No.   Description

 
10.1
  Modification Agreement by and between Neose Technologies, Inc. and General Electric Capital Corporation dated October 31, 2006
EX-10.1 2 exhibit1.htm EX-10.1 EX-10.1

Exhibit 10.1

MODIFICATION AGREEMENT
GE Capital Account Numbers
4139750-003, 004, 008, 009, 010, 014.

THIS MODIFICATION AGREEMENT (“Modification Agreement”) is made and entered into as of this 31st day of October, 2006, by and between GENERAL ELECTRIC CAPITAL CORPORATION (“GE Capital”), a Delaware corporation with a place of business at 83 Wooster Heights Road, 5th Floor, Danbury, CT 06810 and Neose Technologies, Inc. (“Debtor”) a Delaware corporation located at 102 Witmer Road, Horsham, PA 19044.

RECITALS

WHEREAS GE Capital, and Debtor entered into a Master Security Agreement dated as of December 19, 2002, as amended on December 19, 2002, (“Loan Agreement”) for the purpose of providing equipment financing to Debtor. Debtor and GE Capital entered into six promissory notes under the terms of the Loan Agreement (collectively, the “Notes”) under which GE Capital advanced to the Debtor the aggregate sum of Six Million Twelve Thousand Eight Hundred Twenty-Six and Fifty-Eight cents ($6,012,826.58) with current aggregate monthly payments of One Hundred Sixty Thousand Two Hundred Seventy-Two and Seventy-Eight cents ($160,272.78) payable in arrears from the commencement date of each Note. Debtor’s obligations under the Loan Agreement are secured by a lien on all equipment identified on the Notes (“Collateral”);

WHEREAS Debtor has requested that GE Capital modify Debtor’s payment obligations under the Notes;

WHEREAS GE Capital is willing to modify Debtor’s obligations as requested according to the terms and subject to the conditions set forth below.

NOW THEREFORE, in consideration of these premises and the covenants contained herein and for other good and valuable consideration, the receipt and adequacy of which the parties hereby acknowledge, the parties hereby agree as follows:

I. ACKNOWLEDGMENTS, REPRESENTATIONS AND COVENANTS: Debtor represents, acknowledges, warrants and covenants to GE Capital that:

1) The recitals set forth above are true and accurate;

  2)   Debtor has duly executed the Loan Agreement, the Notes, and all other documents related to the financing of the Equipment (the “Loan Documents”) and such Loan Documents set forth continuing obligations of Debtor, enforceable against Debtor in accordance with their respective terms;

  3)   Debtor has adequate power and capacity to enter into this Modification Agreement;

  4)   The entry into and performance by Debtor of its obligations under this Modification Agreement, and the Loan Documents do not (i) violate any judgment, order, law or regulation applicable to Debtor; or (ii) result in any breach of, constitute a default under or result in the creation of any lien, charge, security interest or other encumbrance upon any unit of Equipment pursuant to any indenture, financing agreement, deed of trust, bank loan or credit agreement or other instrument to which Debtor is a party;

  5)   There are no suits or proceedings pending, to Debtor’s knowledge, threatened in court or before any regulatory commission, board or other administrative governmental agency against or affecting Debtor, which would reasonably be expected to have a material adverse effect on the ability of Debtor to fulfill its obligations under this Modification Agreement, and the Loan Documents;

  6)   The most recent financial statements of Debtor delivered to GE Capital accurately present the financial position of Debtor, as of the date of such statements, and there has been no material adverse change in the financial condition of Debtor since the date of such financial statements;

  7)   Notwithstanding any provision of this Modification Agreement to the contrary, Debtor will continue to fulfill any and all of its duties and obligations under the Loan Documents, except as those duties and obligations are modified by this Modification Agreement;

  8)   As of September 1, 2006, after the scheduled monthly payment, there is an aggregate outstanding balance (including principal and interest) on the Notes of Two Million Nine Hundred Thirty Thousand Six Hundred Ninety-One and 29/100 Dollars ($2,930,691.29) along with any unpaid interest remaining to be paid thereon (the “Account Balance”).

II. MODIFICATION:

  1)   The payment schedule and interest rate of the Notes is modified, effective as of the date of this Modification Agreement, as follows:

  (a)   The monthly installment on the Note dated September 17, 2003 is Twelve Thousand Five Hundred Eighty and Thirty-Two Cents ($12,580.32) and the next installment is due and payable on October 1, 2006 with monthly payments on the 1st of each month thereafter with a final installment on June 1, 2007 in the amount of the then outstanding principal and all accrued but unpaid interest.

  (b)   The monthly installment on the Note dated December 18, 2003 is Twenty-Six Thousand Nine Hundred Forty and Seventy-Seven Cents ($26,940.77) and the next installment is due and payable on October 1, 2006 with monthly payments on the 1st of each month thereafter with a final installment on December 1, 2006 the amount of the then outstanding principal and all accrued but unpaid interest.

  (c)   The monthly installment on the Note dated March 30, 2004 is Eighteen Thousand Six Hundred Twenty-One and Thirty-Four Cents ($18,621.34) and the next installment is due and payable on October 1, 2006 with monthly payments on the 1st of each month thereafter with the final installment on December 1, 2007 in the amount of the then outstanding principal and all accrued but unpaid interest.

  (d)   The monthly installment on the Note dated August 20, 2004 is Nineteen Thousand Five Hundred Ninety-Three and Fifty-Five Cents ($19,593.55) and the next installment is due and payable on October 1, 2006 with monthly payments on the 1st of each month thereafter with the final installment on September 1, 2008 in the amount of the then outstanding principal and all accrued but unpaid interest.

  (e)   The monthly installment on the Note dated December 16, 2004 is Sixteen Thousand One Hundred Seventy-One and Seventy-Nine Cents ($16,171.79) and the next installment is due and payable on October 1, 2006 with monthly payments on the 1st of each month thereafter with the final installment, which shall be in the amount of the total outstanding principal and interest, due on May 1, 2008.

  (f)   The monthly installment on the Note dated July 5, 2005 is Eleven Thousand Fifty-Two and Ninety-Two Cents ($11,052.92) and the next installment is due and payable on October 1, 2006 with monthly payments on the 1st of each month thereafter with the final installment on September 1, 2008 in the amount of the then outstanding principal and all accrued but unpaid interest.

III. REMAINING TERMS TO CONTINUE IN EFFECT

  1)   Except as expressly modified above, all conditions and terms of the Note and Master Security Agreement shall continue in full force and effect.

  2)   If this Modification Agreement is deemed unenforceable in any respect, the Note and Master Security Agreement shall be enforceable in accordance with their original terms and conditions as if this Modification Agreement had never been executed.

  3)   It is the intention of the parties hereto to comply with all applicable usury laws; accordingly, it is agreed that, notwithstanding any provision to the contrary in this Modification Agreement, the Note or Master Security Agreement, in no event shall any of the foregoing require the payment or permit the collection of interest in excess of the maximum amount permitted by applicable law. If any such excess interest is contracted for, charged or received thereunder, or in the event that all of the Account Balance shall be prepaid, so that under any of such circumstances the amount of interest contracted for, charged or received under this Modification Agreement, the Note or Master Security Agreement shall exceed the maximum amount of interest permitted by applicable law, then in such event (a) the provisions of this Section shall govern and control, (b) neither Debtor nor any other person or entity now or thereafter liable for the payments shall be obligated to pay the amount of such interest to the extent that it is in excess of the maximum amount of interest permitted by applicable law, (c) any such excess which may have been collected shall be either applied as a credit against the then unpaid Account Balance or refunded to the party having paid same, at the option of GE Capital, and (d) the effective rate of interest shall be automatically reduced to the maximum lawful contract rate allowed under applicable law as now or hereafter construed by the courts having jurisdiction thereof.

  4)   Any payment received from Debtor may be applied by GE Capital at any time against any obligation due and owing by Debtor under the Notes or Master Security Agreement, in GE Capital’s sole discretion, notwithstanding any statement appearing on or referred to in any remittance from Debtor or any prior application of such payment. In the event any bankruptcy proceedings are instituted by or against Debtor under any applicable bankruptcy law within 90 days after receipt by GE Capital of any such payment, such payment shall be deemed applicable to unpaid obligations then due hereunder in the inverse order of maturity.

  5)   Debtor hereby certifies, agrees and acknowledges that the Equipment is installed and fully operational and is now and will continue to be used and in the conduct of Debtor’s business.

  6)   This Modification Agreement shall be binding upon and shall inure to the benefit of all the parties hereto and their respective administrators, successors and permitted assigns.

IN WITNESS WHEREOF, the parties hereto have executed this Modification Agreement and have caused this Modification Agreement to be executed by their respective duly authorized representatives as of the day first above-written.

NEOSE TECHNOLOGIES, INC.

By: /s/ A. Brian Davis     
Title: Senior Vice President and CFO

GENERAL ELECTRIC CAPITAL CORPORATION

By: /s/ John Edel     
Title: SVP     

-----END PRIVACY-ENHANCED MESSAGE-----